跳至主要内容
临床试验/NCT00738660
NCT00738660已完成3 期

Efficacy of Telmisartan and the Combination of Telmisartan and Ramipril in type1 Diabetes Patients With Nephropathy

Post Graduate Institute of Medical Education and Research, Chandigarh1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2007年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
30
试验地点
1
主要终点
Reduction in albumin excretion rate

研究概览

简要总结

Hypothesis:

The angiotensin receptor blocker telmisartan is effective at reduction of albumin excretion rate(AER) in patients with type1 diabetes and micro or macroalbuminuria. Dual blockade with the addition of ramipril an angiotensin receptor blocker gives added efficacy for reduction of AER. ARB telmisartan gives a 24 hr BP lowering effect.

Summary:

This is an open label cross over study involving 30 patients who were initially treated with Telmisartan 80 mg for eight weeks followed by addition of Ramipril 10 mg for a further eight weeks. Albuminuria reduction and BP reduction with both clinic and ambulatory BP records were studied at the end of each phase.

详细描述

To evaluate the antialbuminuric efficacy of an angiotensin receptor blocker (ARB) telmisartan and the combination of telmisartan and ramipril in patients with type1 DM and either micro or macroalbuminuria.To evaluate the same drugs for their antihypertensive efficacy and their influence on dipping patterns using ambulatory BP monitoring.

Methods:

Open label cross over study involving 30 patients who were initially treated with telmisartan 80 mg for eight weeks followed by addition of ramipril 10 mg for a further eight weeks. Albuminuria reduction and BP reduction with both clinic and ambulatory BP records were studied at the end of each phase Overnight urine samples of nine hours duration were collected . The volume of urine was verified by measurement in a jar with accuracy of 50ml by the study investigator on every occasion. . Albuminuria was estimated by immuno-turbidimetry Hemocue albumin system Angelholm AD, Sweden (inter assay CV 4.3% ). The albumin excretion rate(AER) at baseline evaluation was determined as the mean AER of the positive urine samples. During subsequent evaluations at the end of 8weeks and at the end of 16 weeks the mean albumin excretion rate from two successive overnight urine samples was taken as the mean .Ambulatory BP (ABP) measurement :ABP was measured using Spacelabs device 90207 Spacelabs inc. use of which is described before(14) .A uniform protocol of inflation once in every 30 min was used. Cuff was applied to the nondominant arm. Recordings were started in all patients between seven and ten AM.

研究设计

研究类型
Interventional
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
14 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diabetes mellitus by ADA criteria
  • Clinical history of DKA
  • HbA1C < 7.5,urine AER >/= 20 mcg/min on two overnight urine samples

排除标准

  • Pregnancy
  • Unwillingness to use contraception during time of study
  • Creatinine >3 mg/dl
  • Suspected/proven non diabetic nephropathy
  • Active urinary sediment

研究组 & 干预措施

A

Experimental

single experimental arm cross over of patients, addition of Ramipril onto Telmisartan.

干预措施: Telmisartan, Ramipril (Drug)

结局指标

主要结局

Reduction in albumin excretion rate

时间窗: 8 weeks

次要结局

  • 24 hr ambulatory BP reduction,nocturnal BP reduction, proportion of dippers(8weeks)

研究者

发起方
Post Graduate Institute of Medical Education and Research, Chandigarh
申办方类型
Other

研究点 (1)

Loading locations...

相似试验